Drug intelligence / Profile preview

AR-101

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

AR-101 is one of the two enantiomers of iclaprim, a novel dihydrofolate reductase (DHFR) inhibitor belonging to the 2,4-diaminopyrimidine class of antibiotics. It exhibits potent bactericidal activity against major Gram-positive pathogens, including methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA) phenotypes, even those resistant to trimethoprim (TMP). AR-101 acts as a competitive inhibitor with respect to the substrate dihydrofolate.

Targets

DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on AR-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR-101.

Explore the full profile